Drug-development diligence often spans clinical trials, publications, regulatory records, patents, company filings, internal notes, and licensed sources.
The difficulty is not only finding a document. The team also needs to know why the document matters, which claim it supports, who reviewed it, what assumptions remain, and which source rights apply.
This article is an editorial workflow-design example. It is not a customer case study, a public AuraOne product, or proof that AuraOne currently connects the sources named below.
Start with the current operation
Before software or a model is selected, a team should document:
- The asset, target, company, indication, or program under review.
- The decision the diligence work must support.
- The current SOP, participants, volume, timing, and budget owner.
- The public, licensed, and internal source classes the team may use.
- The claims, assumptions, risks, gaps, and review states the output must retain.
- The accepted handoff format and baseline for time, cost, and quality.
That current-state record determines whether the workflow is repeatable enough to standardize and whether AuraOne has a defensible role in running it.
Source boundaries
Relevant open-source interfaces may include:
- ClinicalTrials.gov for clinical-study records.
- PubMed and other literature indexes for publications.
- FDA public resources for regulatory and label context.
- PatentsView for patent metadata.
- ChEMBL and PubChem for chemistry context.
- Open Targets for target-related evidence.
- SEC EDGAR for public company filings.
A named source is an example, not a claim that an AuraOne production connector is configured. Customer systems and licensed providers require authorization, credentials, contractual access, security review, and rights appropriate to the intended use.
Assisted research can support discovery, but search results, summaries, and unverified pages should not become authoritative claims merely because they were retrieved.
A bounded workflow
A credible design-partner workflow would follow a sequence like this:
Intake. Define the asset, diligence question, intended use, source rules, output, review policy, and acceptance criteria.
Collect. Associate allowed public and customer-provided sources with the asset record while retaining retrieval and rights context.
Review. Let qualified reviewers accept, reject, edit, or flag source material and claims. Keep disagreement and unresolved questions visible.
Prepare. Organize evidence, assumptions, risks, gaps, and next-step questions into the agreed output.
Deliver. Produce a stored, downloadable record with included source references, review states, manifest, and handoff terms.
Measure. Compare cycle time, cost, review quality, and rework with the customer's current baseline.
This workflow would support research and diligence organization. It would not provide medical advice, make clinical decisions, replace legal or regulatory review, or guarantee an investment or development outcome.
Where automation may fit
Automation should be admitted step by step. Retrieval, extraction, deduplication, classification, and draft synthesis may be candidates when the team has a reliable benchmark and a human escalation path.
The workflow should preserve complete inputs, tool actions, reviewer corrections, and accepted outputs when the customer has authorized that use. Repeated, rights-cleared traces may later support evaluation or model specialization. That possibility is not a day-one deliverable and should never be promised before the data and economics justify it.
The admission test
AuraOne should consider this type of engagement only when a named customer has:
- A workflow it performs today.
- Measurable volume, cost, delay, or quality pain.
- Digital or capturable inputs and an objectively reviewable output.
- Access to required systems and legal rights to the data and traces.
- A named budget owner and human escalation path.
- Plausible economics after labor, inference, integration, and support.
Without those conditions, "drug-development diligence" is an industry idea, not a product.
Official source interfaces
Continue with the current product direction